PATENT CLAIM ANALYSIS

Application Number: 16130801
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["544", "350000"]

Abstract:
The present invention is directed to imidazo[1,2-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Claim (Index 68):
The method of  claim 59 , wherein R 1  is pyrrolidin-3-ylmethoxy, 2-pyrrolidin-3-ylethyl, (pyrrolidin-3-yloxy)methyl, [3-(dimethylamino)pyrrolidin-1-yl]methyl, [3-(dimethylamino)pyrrolidin-1-yl]ethyl, (1-methylpyrrolidin-3-yl)oxy, 3-(dimethylamino)propoxy, piperidin-3-ylmethoxy, (1-methylpyrrolidin-3-ylmethoxy, (1-methylpiperidin-3-ylmethoxy, (pyrrolidin-3-ylmethylthio, 4-(dimethylamino)piperidin-1-yl, [3-(dimethylamino)propyl](methyl)amino, [2-(1-methylpyrrolidin-2-yl)ethyl]amino, (1-methylpiperidin-4-yl)amino, 4-methyl-1,4-diazepan-1-yl, 2,7-diazaspiro[4.4]non-2-yl, 2,7-diazaspiro[3.5]non-7-yl, 3-(dimethylamino)-N-methylpyrrolidinyl, [2-(2-amino-1,3-thiazol-4-yl)ethyl]amino, azetidin-3-ylmethylaminocarbonyl, 3-(dimethylamino)piperidin-1-yl, [1-(2-hydroxyethyl)piperidin-3-yl]methoxy, [1-(2-cyanoethyl)piperidin-3-yl]methoxy, (1-ethylpiperidin-3-ylmethoxy, or 1-methylazetidin-3-ylaminocarbonyl.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 97.0
- Lexical Diversity: 1.0
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14795466', '15613361', '15610015', '14795536', '16038924']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8313678393158636
- 35 USC 102 Novelty (BERT): 0.6525777713154531
- Combined Prediction Score: 0.8134888325158226
- Mean Citation Score: 619.088486
- Max Citation Score: 655.64526
- Similarity Product: 595.3510191981376

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test